What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025Blood

Efficacy and safety of azacitidine plus low-dose dasatinib maintenance therapy for patients with intermediate and high-risk acute myeloid leukemia: A prospective, randomized, phase Ⅱ clinical trial

View Full Paper

Ask AI

Bookmark

Authors

JJJinli JianLanzhou University

Discussion

Member takes

Implication

Randomized trial shows improved overall survival in high-risk acute myeloid leukemia patients receiving azacitidine plus dasatinib, indicating a promising maintenance therapy.

Key Points

AZA plus Dasatinib treatment achieved better overall survival in high-risk AML patients compared to AZA alone.
The median overall survival was 26 months with AZA alone, while AZA plus Dasatinib had not reached a median.
Phase II trial enrolled newly diagnosed AML patients, comparing the efficacy of AZA alone versus AZA combined with Dasatinib.
Findings suggest that combining AZA with low-dose Dasatinib may be a novel treatment option for AML patients.

Cite This Study

Jinli Jian (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e39a https://doi.org/10.1182/blood-2025-1002

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows improved overall survival in high-risk acute myeloid leukemia patients receiving azacitidine plus dasatinib, indicating a promising maintenance therapy.

Efficacy and safety of azacitidine plus low-dose dasatinib maintenance therapy for patients with intermediate and high-risk acute myeloid leukemia: A prospective, randomized, phase Ⅱ clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of azacitidine plus low-dose dasatinib maintenance therapy for patients with intermediate and high-risk acute myeloid leukemia: A prospective, randomized, phase Ⅱ clinical trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider